ARTICLE | Company News
AcelRx, Gruenenthal sales and marketing update
December 23, 2013 8:00 AM UTC
AcelRx granted Gruenenthal commercialization rights in Europe and Australia to Zalviso sufentanil sublingual microtablet system for pain. AcelRx will receive $30 million up front and is eligible for ...